Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CBLL

Ceribell Inc

Feb 13 • 02:23PM ET

20.10

+0.16 0.80 %

Healthcare • Medical Devices • USA • NASD

Held by: VTI IWM VXF IWO VTWO SCHA LFSC IWC ITOT VHT

Index	RUT	P/E	-	EPS (ttm)	-1.45	Insider Own	39.58%	Shs Outstand	37.05M	Perf Week	-0.25%
Market Cap	745.63M	Forward P/E	-	EPS next Y	-1.46	Insider Trans	-3.05%	Shs Float	22.41M	Perf Month	-12.34%
Enterprise Value	598.43M	PEG	-	EPS next Q	-0.41	Inst Own	56.37%	Short Float	7.25%	Perf Quarter	56.42%
Income	-52.46M	P/S	9.00	EPS this Y	55.56%	Inst Trans	-0.48%	Short Ratio	3.55	Perf Half Y	70.48%
Sales	82.81M	P/B	4.54	EPS next Y	3.00%	ROA	-42.55%	Short Interest	1.63M	Perf YTD	-8.34%
Book/sh	4.43	P/C	4.42	EPS next 5Y	33.42%	ROE	-59.78%	52W High	26.04 -22.81%	Perf Year	-8.22%
Cash/sh	4.54	P/FCF	-	EPS past 3/5Y	-1.63% -	ROIC	-28.47%	52W Low	10.01 100.80%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	58.89% -	Gross Margin	87.99%	Volatility	6.92% 4.97%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7.23	EPS Y/Y TTM	-	Oper. Margin	-68.46%	ATR (14)	1.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.11	Sales Y/Y TTM	-	Profit Margin	-63.35%	RSI (14)	44.01	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.50	EPS Q/Q	-25.79%	SMA20	-4.00%	Beta	1.02	Target Price	28.14
Payout	-	Debt/Eq	0.13	Sales Q/Q	31.37%	SMA50	-5.35%	Rel Volume	0.33	Prev Close	19.94
Employees	281	LT Debt/Eq	0.12	Earnings	Feb 24 AMC	SMA200	24.38%	Avg Volume	458.40K	Price	20.10
IPO	Oct 11, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.67% 3.76%	Trades		Volume	114,893	Change	0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Raymond James	Strong Buy	$19
Jun-24-25	Initiated	BTIG Research	Buy	$30
Apr-04-25	Initiated	Ladenburg Thalmann	Buy	$32
Nov-05-24	Initiated	William Blair	Outperform
Nov-05-24	Initiated	TD Cowen	Buy	$31
Nov-05-24	Initiated	JP Morgan	Overweight	$32
Nov-05-24	Initiated	Canaccord Genuity	Buy	$30
Nov-05-24	Initiated	BofA Securities	Buy	$32

Feb-10-26 04:05PM	Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
Jan-14-26 09:21AM	CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion (MarketBeat)
Jan-06-26 12:34PM	CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection (Zacks)
Jan-05-26 08:00AM	Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution (GlobeNewswire)
Dec-30-25 04:05PM	Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
10:02AM	Loading…
Dec-12-25 10:02AM	CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution (Zacks)
09:49AM	AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs (PR Newswire)
Dec-09-25 08:00AM	Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution (GlobeNewswire)
Nov-24-25 08:00AM	Ceribell Receives FDA 510(k) Clearance for Use of Clarity? Algorithm for Neonates (GlobeNewswire)
Nov-19-25 04:05PM	Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 04:05PM	Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Nov-05-25 12:06AM	CeriBell Inc (CBLL) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com) +7.88%
Nov-04-25 06:05PM	CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Ceribell Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-29-25 10:00AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks) -6.24%
10:00AM	Loading…
Oct-28-25 10:00AM	CeriBell, Inc. (CBLL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-21-25 04:05PM	Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire) +7.04%
Sep-22-25 08:00AM	Medtech Leader Erica Rogers Joins Ceribell Board of Directors (GlobeNewswire)
Aug-13-25 12:08PM	J.P. Morgan Maintains a Buy Rating on CeriBell (CBLL) With a $21 PT (Insider Monkey)
Aug-05-25 04:05PM	Ceribell Reports Second Quarter 2025 Financial Results (GlobeNewswire) -15.25%
Jul-29-25 04:05PM	Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
03:20PM	Medtech IPOs Spur Talk of Broader US Health-Care Listing Revival (Bloomberg)
Jul-22-25 04:05PM	Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire)
Jul-07-25 04:42PM	Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware (GlobeNewswire) -9.14%
Jun-20-25 09:11AM	AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape (PR Newswire)
May-29-25 05:44AM	The medtech IPO window is finally open. Or is it? (MedTech Dive)
May-20-25 04:05PM	Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference (GlobeNewswire)
May-09-25 03:43AM	CeriBell Inc (CBLL) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Amid ... (GuruFocus.com) -6.61%
May-08-25 04:05PM	Ceribell Reports First Quarter 2025 Financial Results (GlobeNewswire) +6.81%
Apr-30-25 04:05PM	Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference (GlobeNewswire)
08:00AM	Loading…
08:00AM	Ceribell Receives FedRAMP High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems (GlobeNewswire)
Apr-24-25 04:05PM	Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-23-25 02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 05:00AM	Ceribell wins FDA nod for algorithm to detect pediatric seizures (MedTech Dive)
Apr-16-25 10:40AM	CBLL Stock Falls Despite FDA Clearance for Pediatric Clarity Algorithm (Zacks)
Apr-15-25 08:00AM	FDA Clears Ceribell's Clarity Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older (GlobeNewswire)
Apr-07-25 01:04PM	CeriBell's IPO Lockup Ends April 9 - Here's Why We're Shorting It Today (Seeking Alpha)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Feb-26-25 02:15AM	CeriBell Inc (CBLL) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Amid ... (GuruFocus.com)
Feb-25-25 04:05PM	Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-18-25 04:05PM	Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-11-25 04:05PM	Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
Dec-23-24 04:05PM	Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-19-24 08:00AM	Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing (GlobeNewswire)
07:01AM	Meet the biophysicist whose seizure-detection company is using AI to get a better read on peoples brains (FastCompany)
Nov-13-24 11:55PM	Ceribell, Inc. Reports Strong Q3 2024 Growth (TipRanks)
Nov-12-24 04:05PM	Ceribell Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-11-24 08:00AM	Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs (GlobeNewswire)
Nov-07-24 04:05PM	Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Nov-06-24 06:31AM	Ceribell initiated with a Buy at BofA on differentiated AI algorithm (TipRanks)
Oct-29-24 04:05PM	Ceribell to Report Third Quarter 2024 Financial Results on November 12, 2024 (PR Newswire)
Oct-18-24 01:01AM	TPG GP A, LLC Acquires New Stake in CeriBell Inc (GuruFocus.com)
Oct-16-24 04:05PM	New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG (PR Newswire)
Oct-15-24 05:00PM	CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Oct-11-24 05:00PM	CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs (Bloomberg)
10:15AM	CeriBell IPO: Stock price soars as AI brain-monitoring headband maker debuts on Nasdaq (FastCompany)
08:45AM	Upstream Bio Leads Life Sciences IPOs With Upsized Listing (Bloomberg)
Oct-10-24 11:27PM	CeriBell, Inc. Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Ceribell, Inc. is a commercial-stage medical technology company, which engages in the provision of transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point-of-Care EEG, which enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies, Clarity, an AI algorithm that interprets EEG in real-time, providing bedside alerts and continuous monitoring for status epilepticus, and EEG Portal, which makes it easy to remotely review EEG in real-time with pre-annotated EEG insights. The company was founded by Xing Juan Chao, Josef Parvizi, and Chris Chafe on August 29, 2014 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chao Xingjuan	President and CEO	Feb 04 '26	Option Exercise	4.70	25,000	117,500	750,802	Feb 06 03:51 PM
Chao Xingjuan	President and CEO	Feb 04 '26	Sale	20.16	39,000	786,240	727,248	Feb 06 03:51 PM
Foehr David	Senior VP, Finance and PAO	Feb 03 '26	Option Exercise	4.70	5,556	26,113	22,303	Feb 05 12:54 PM
Foehr David	Senior VP, Finance and PAO	Feb 03 '26	Sale	20.00	5,556	111,120	18,900	Feb 05 12:54 PM
Woo Raymond	Chief Technology Officer	Feb 02 '26	Option Exercise	4.37	11,112	48,605	174,232	Feb 04 04:01 PM
Woo Raymond	Chief Technology Officer	Feb 02 '26	Sale	20.55	11,112	228,375	167,617	Feb 04 04:01 PM
Chao Xingjuan	Officer	Feb 04 '26	Proposed Sale	20.51	39,000	799,890		Feb 04 02:38 PM
Foehr David	Officer	Feb 03 '26	Proposed Sale	20.00	5,556	111,120		Feb 03 10:35 AM
Woo Raymond	Officer	Feb 02 '26	Proposed Sale	20.80	11,112	231,130		Feb 02 03:24 PM
Parvizi Josef	Director	Jan 15 '26	Sale	22.94	25,000	573,500	747,652	Jan 20 04:52 PM
Parvizi Josef	Director	Jan 15 '26	Proposed Sale	22.94	25,000	573,453		Jan 15 04:24 PM
Foehr David	Senior VP, Finance and PAO	Jan 05 '26	Option Exercise	4.70	5,556	26,113	22,303	Jan 07 07:12 PM
Foehr David	Senior VP, Finance and PAO	Jan 05 '26	Sale	22.60	5,556	125,566	18,900	Jan 07 07:12 PM
Chao Xingjuan	President and CEO	Jan 05 '26	Option Exercise	4.70	25,000	117,500	764,802	Jan 07 06:09 PM
Chao Xingjuan	President and CEO	Jan 05 '26	Sale	21.27	79,000	1,680,048	741,248	Jan 07 06:09 PM
Woo Raymond	Chief Technology Officer	Jan 02 '26	Option Exercise	4.37	11,112	48,605	173,932	Jan 06 05:16 PM
Woo Raymond	Chief Technology Officer	Jan 02 '26	Sale	21.18	11,112	235,382	167,317	Jan 06 05:16 PM
ROBERTSON REBECCA B	Director	Jan 02 '26	Option Exercise	2.24	2,500	5,600	22,076	Jan 06 05:16 PM
ROBERTSON REBECCA B	Director	Jan 02 '26	Sale	21.89	2,500	54,725	19,576	Jan 06 05:16 PM
Chao Xingjuan	Officer	Jan 05 '26	Proposed Sale	21.27	79,000	1,680,125		Jan 05 04:46 PM
Foehr David	Officer	Jan 05 '26	Proposed Sale	22.60	5,556	125,566		Jan 05 11:02 AM
ROBERTSON REBECCA B	Director	Jan 02 '26	Proposed Sale	21.89	2,500	54,725		Jan 02 11:21 AM
Woo Raymond	Officer	Jan 02 '26	Proposed Sale	21.89	11,112	243,242		Jan 02 10:52 AM
Blumberg Scott	Chief Financial Officer	Dec 22 '25	Option Exercise	4.23	36,000	152,105	138,561	Dec 29 01:40 PM
Blumberg Scott	Chief Financial Officer	Dec 22 '25	Sale	21.00	36,000	756,000	118,842	Dec 29 01:40 PM
Blumberg Scott	Officer	Dec 22 '25	Proposed Sale	21.00	36,000	756,000		Dec 22 10:01 AM
Parvizi Josef	Director	Dec 15 '25	Sale	21.49	25,000	537,250	772,652	Dec 17 08:07 PM
Parvizi Josef	Director	Dec 15 '25	Proposed Sale	21.55	25,000	538,650		Dec 15 04:34 PM
BURKE WILLIAM W	Director	Dec 09 '25	Option Exercise	3.97	32,728	130,085	40,391	Dec 11 04:48 PM
BURKE WILLIAM W	Director	Dec 09 '25	Sale	22.02	32,728	720,671	17,391	Dec 11 04:48 PM
Parvizi Josef	Director	Dec 08 '25	Sale	20.26	25,000	506,500	797,652	Dec 10 08:00 PM
ROBERTSON REBECCA B	Director	Dec 08 '25	Option Exercise	2.24	5,000	11,200	13,388	Dec 10 01:02 PM
ROBERTSON REBECCA B	Director	Dec 08 '25	Sale	20.00	5,000	100,000	8,388	Dec 10 01:02 PM
BURKE WILLIAM W	Director	Dec 09 '25	Proposed Sale	22.02	32,728	720,688		Dec 09 04:05 PM
Parvizi Josef	Director	Dec 08 '25	Proposed Sale	20.26	25,000	506,467		Dec 08 04:28 PM
Chao Xingjuan	President and CEO	Dec 04 '25	Option Exercise	2.24	25,000	56,000	823,135	Dec 08 01:01 PM
Chao Xingjuan	President and CEO	Dec 04 '25	Sale	18.82	25,000	470,500	798,135	Dec 08 01:01 PM
ROBERTSON REBECCA B	Director	Dec 08 '25	Proposed Sale	20.00	5,000	100,000		Dec 08 12:27 PM
Foehr David	Senior VP, Finance and PAO	Dec 03 '25	Option Exercise	4.70	4,399	20,675	21,630	Dec 05 05:35 PM
Foehr David	Senior VP, Finance and PAO	Dec 03 '25	Sale	16.83	5,265	88,610	19,384	Dec 05 05:35 PM
Chao Xingjuan	Officer	Dec 04 '25	Proposed Sale	18.82	25,000	470,534		Dec 04 04:44 PM
ROBERTSON REBECCA B	Director	Dec 02 '25	Sale	16.67	827	13,786	8,388	Dec 04 02:16 PM
Woo Raymond	Chief Technology Officer	Dec 01 '25	Option Exercise	4.37	11,112	48,605	178,816	Dec 03 01:34 PM
Woo Raymond	Chief Technology Officer	Dec 01 '25	Sale	12.28	11,112	136,455	167,704	Dec 03 01:34 PM
Chao Xingjuan	President and CEO	Dec 01 '25	Option Exercise	3.65	25,000	91,250	823,135	Dec 03 01:33 PM
Chao Xingjuan	President and CEO	Dec 01 '25	Sale	16.59	25,000	414,750	798,135	Dec 03 01:33 PM
Foehr David	Officer	Dec 03 '25	Proposed Sale	16.83	5,265	88,610		Dec 03 10:06 AM
ROBERTSON REBECCA B	Director	Dec 02 '25	Proposed Sale	16.67	827	13,786		Dec 02 09:50 AM
Chao Xingjuan	Officer	Dec 01 '25	Proposed Sale	16.87	25,000	421,750		Dec 01 12:20 PM
Woo Raymond	Officer	Dec 01 '25	Proposed Sale	16.87	11,112	187,459		Dec 01 10:17 AM
Chao Xingjuan	President and CEO	Nov 21 '25	Option Exercise	2.94	50,000	147,250	848,135	Nov 25 06:39 PM
Chao Xingjuan	President and CEO	Nov 21 '25	Sale	15.13	50,000	756,500	798,135	Nov 25 06:39 PM
Chao Xingjuan	Officer	Nov 21 '25	Proposed Sale	15.13	50,000	756,539		Nov 21 04:52 PM
Woo Raymond	Chief Technology Officer	Nov 11 '25	Option Exercise	4.37	11,112	48,605	178,816	Nov 13 01:50 PM
Woo Raymond	Chief Technology Officer	Nov 11 '25	Sale	12.28	11,112	136,455	167,704	Nov 13 01:50 PM
Woo Raymond	Officer	Nov 11 '25	Proposed Sale	12.28	11,112	136,497		Nov 12 07:12 AM
Woo Raymond	Chief Technology Officer	Oct 03 '25	Option Exercise	4.37	11,112	48,605	178,816	Oct 07 06:29 PM
Woo Raymond	Chief Technology Officer	Oct 03 '25	Sale	12.54	11,112	139,344	167,704	Oct 07 06:29 PM
Woo Raymond	Officer	Oct 03 '25	Proposed Sale	12.54	11,112	139,315		Oct 03 04:40 PM
Woo Raymond	Chief Technology Officer	Sep 04 '25	Option Exercise	4.37	11,112	48,605	178,816	Sep 08 01:28 PM
Woo Raymond	Chief Technology Officer	Sep 04 '25	Sale	12.11	11,112	134,566	167,704	Sep 08 01:28 PM
ROBERTSON REBECCA B	Director	Sep 03 '25	Sale	11.36	827	9,395	9,215	Sep 05 02:33 PM
Woo Raymond	Officer	Sep 04 '25	Proposed Sale	12.11	11,112	134,610		Sep 04 04:13 PM
Woo Raymond	Chief Technology Officer	Sep 02 '25	Option Exercise	2.24	20,000	44,800	167,704	Sep 04 12:58 PM
ROBERTSON REBECCA B	Director	Sep 03 '25	Proposed Sale	11.36	827	9,395		Sep 03 10:34 AM
Foehr David	Senior VP, Finance and PAO	Aug 27 '25	Sale	11.71	866	10,141	20,250	Aug 29 12:06 PM
Foehr David	Officer	Aug 27 '25	Proposed Sale	11.71	866	10,143		Aug 27 04:50 PM
Taylor Joseph Michael	Director	Aug 19 '25	Sale	11.76	7,032	82,696	59,235	Aug 21 02:47 PM
Taylor Joseph Michael	Director	Aug 19 '25	Proposed Sale	11.76	7,032	82,690		Aug 19 05:12 PM
Chao Xingjuan	President and CEO	Jul 07 '25	Option Exercise	2.24	25,000	56,000	801,222	Jul 09 02:49 PM
Chao Xingjuan	President and CEO	Jul 07 '25	Sale	17.70	25,000	442,500	776,022	Jul 09 02:49 PM
Chao Xingjuan	Officer	Jul 07 '25	Proposed Sale	18.80	25,000	470,000		Jul 07 01:07 PM
ROBERTSON REBECCA B	Director	Jun 18 '25	Sale	17.85	11,188	199,706	10,042	Jun 20 12:31 PM
ROBERTSON REBECCA B	Director	Jun 17 '25	Sale	17.63	7,445	131,255	21,230	Jun 20 12:31 PM
Copp Joshua	Former Officer	Jun 18 '25	Proposed Sale	17.85	11,188	199,715		Jun 18 01:23 PM
ROBERTSON REBECCA B	Director	Jun 16 '25	Option Exercise	3.61	20,000	72,232	48,675	Jun 17 07:52 PM
ROBERTSON REBECCA B	Director	Jun 16 '25	Sale	17.14	20,000	342,800	28,675	Jun 17 07:52 PM
ROBERTSON REBECCA B	Director	Jun 17 '25	Proposed Sale	17.09	7,445	127,235		Jun 17 10:19 AM
ROBERTSON REBECCA B	Director	Jun 16 '25	Proposed Sale	17.14	20,000	342,738		Jun 16 04:17 PM
Copp Joshua	Former Officer	Jun 13 '25	Proposed Sale	18.00	6,859	123,484		Jun 13 04:22 PM
Chao Xingjuan	President and CEO	Jun 03 '25	Option Exercise	2.24	25,000	56,000	801,022	Jun 05 06:34 PM
Chao Xingjuan	President and CEO	Jun 03 '25	Sale	17.00	25,000	425,000	776,022	Jun 05 06:34 PM
Chao Xingjuan	Officer	Jun 03 '25	Proposed Sale	17.15	25,000	428,750		Jun 03 10:06 AM
Chao Xingjuan	President and CEO	May 15 '25	Option Exercise	1.02	73,871	75,060	776,022	May 19 12:33 PM
Chao Xingjuan	President and CEO	May 15 '25	Sale	16.96	25,000	424,000	727,151	May 19 12:33 PM
Chao Xingjuan	Officer	May 15 '25	Proposed Sale	16.59	25,000	414,750		May 15 10:47 AM
Chao Xingjuan	President and CEO	Apr 23 '25	Sale	15.11	15,628	236,139	727,151	Apr 24 04:47 PM
Chao Xingjuan	President and CEO	Apr 22 '25	Sale	15.06	300	4,518	742,779	Apr 24 04:47 PM
Chao Xingjuan	Officer	Apr 23 '25	Proposed Sale	15.11	15,628	236,085		Apr 23 04:11 PM
Chao Xingjuan	Officer	Apr 22 '25	Proposed Sale	15.06	300	4,518		Apr 22 04:10 PM
Chao Xingjuan	President and CEO	Apr 17 '25	Sale	15.02	5,700	85,614	746,451	Apr 21 09:31 PM
Chao Xingjuan	President and CEO	Apr 21 '25	Sale	15.03	3,372	50,681	743,079	Apr 21 09:31 PM
Chao Xingjuan	Officer	Apr 21 '25	Proposed Sale	15.03	3,372	50,664		Apr 21 04:07 PM
Chao Xingjuan	Officer	Apr 17 '25	Proposed Sale	15.02	5,700	85,612		Apr 17 04:13 PM

Open in Screener

RXST

RxSight Inc

Feb 13 • 02:23PM ET

8.11

+0.31 3.97 %

Healthcare • Medical Devices • USA • NASD

Peers: STAA ALGN ICUI EW BSX MDT SYK TFX BAX XRAY

| Held by: VTI IWM VXF IWO VTWO SCHA VHT XHE DFAS ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.88	Insider Own	6.26%	Shs Outstand	41.08M	Perf Week	-3.34%
Market Cap	333.46M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	0.00%	Shs Float	38.54M	Perf Month	-16.13%
Enterprise Value	117.50M	PEG	-	EPS next Q	-0.33	Inst Own	81.79%	Short Float	10.75%	Perf Quarter	-18.98%
Income	-35.73M	P/S	2.35	EPS this Y	-50.09%	Inst Trans	-12.37%	Short Ratio	4.35	Perf Half Y	-1.34%
Sales	142.09M	P/B	1.21	EPS next Y	-4.03%	ROA	-11.54%	Short Interest	4.14M	Perf YTD	-22.17%
Book/sh	6.72	P/C	1.47	EPS next 5Y	-14.11%	ROE	-12.92%	52W High	32.24 -74.85%	Perf Year	-74.55%
Cash/sh	5.53	P/FCF	-	EPS past 3/5Y	26.50% -	ROIC	-12.48%	52W Low	6.32 28.32%	Perf 3Y	-39.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	83.64% 128.61%	Gross Margin	74.98%	Volatility	6.40% 6.05%	Perf 5Y	-
Dividend TTM	-	EV/Sales	0.83	EPS Y/Y TTM	-7.15%	Oper. Margin	-32.01%	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.44	Sales Y/Y TTM	10.75%	Profit Margin	-25.15%	RSI (14)	37.00	Recom	3.09
Dividend Gr. 3/5Y	- -	Current Ratio	12.74	EPS Q/Q	-50.41%	SMA20	-7.84%	Beta	1.15	Target Price	10.39
Payout	-	Debt/Eq	0.04	Sales Q/Q	-14.09%	SMA50	-21.21%	Rel Volume	0.34	Prev Close	7.80
Employees	498	LT Debt/Eq	0.04	Earnings	Feb 25 AMC	SMA200	-22.43%	Avg Volume	952.22K	Price	8.11
IPO	Jul 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.12% 19.87%	Trades		Volume	247,877	Change	3.97%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Initiated	William Blair	Mkt Perform
Jul-15-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$9
Jul-10-25	Downgrade	Jefferies	Buy → Hold	$9
Jul-09-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$9
Jul-09-25	Downgrade	Oppenheimer	Outperform → Perform
Jul-09-25	Downgrade	BTIG Research	Buy → Neutral
May-19-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$25
Apr-15-25	Initiated	Piper Sandler	Neutral	$18
Apr-09-25	Downgrade	UBS	Buy → Neutral	$16
Apr-04-25	Downgrade	JP Morgan	Overweight → Underweight	$40 → $17
Apr-03-25	Downgrade	BofA Securities	Buy → Underperform	$36 → $22
Dec-20-24	Downgrade	Stifel	Buy → Hold	$65 → $40
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$56 → $42
Dec-06-24	Initiated	UBS	Buy	$52
Oct-29-24	Initiated	Jefferies	Buy	$72
Aug-20-24	Reiterated	Needham	Buy	$54 → $66
Aug-06-24	Reiterated	Needham	Buy	$75 → $54
May-07-24	Reiterated	BTIG Research	Buy	$61 → $72
Dec-13-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$31 → $42
Dec-12-23	Initiated	Stifel	Buy	$40

Show Previous Ratings

Feb-11-26 04:10PM	RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (GlobeNewswire)
03:15PM	RxSight, Inc. (RXST) Initiated at Market Perform as Firm Seeks Sales Reacceleration (Insider Monkey)
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
Jan-13-26 06:16AM	RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-11-26 09:30AM	RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer (GlobeNewswire)
04:05PM	Loading…
Jan-02-26 04:05PM	RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-25 12:42PM	RxSight CFO exit raises concerns over pace of recovery, BTIG says (Investing.com) -9.98%
Dec-22-25 05:15PM	RxSight, Inc. Announces Chief Financial Officer Transition (GlobeNewswire)
Nov-20-25 04:05PM	RxSight, Inc. to Present at the Piper Sandler Healthcare Conference (GlobeNewswire) -5.79% +13.41%
Nov-06-25 12:04AM	RxSight Inc (RXST) Q3 2025 Earnings Call Highlights: Navigating Growth Amid Revenue Challenges (GuruFocus.com)
Nov-05-25 06:50PM	RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.33%
04:05PM	RxSight, Inc. Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:31AM	RxSight Inc (RXST) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-22-25 04:05PM	RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-16-25 04:05PM	RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting (GlobeNewswire) +7.34%
08:45AM	Loading…
Sep-16-25 08:45AM	Investors in RxSight, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - RXST (PR Newswire)
Sep-15-25 09:32AM	RxSight (RXST) Fell Due to Missed Expectations and Guidance Reduction (Insider Monkey)
Sep-09-25 09:00AM	RxSight, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - RXST (PR Newswire) +9.40%
Sep-05-25 04:09PM	Investors in RxSight, Inc. (RXST): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile)
Sep-04-25 03:59PM	Investors Urged to Contact Levi & Korsinsky for Information Before September 22, 2025 - RxSight, Inc. (RXST) (Newsfile)
Aug-25-25 04:05PM	RxSight, Inc. to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire) -7.22%
Aug-22-25 08:45AM	RxSight, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RXST (PR Newswire) +6.30%
Aug-14-25 04:05PM	RxSight, Inc. to Present at the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-25 05:14PM	Investors in RxSight, Inc. (RXST): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile) +13.06%
Aug-12-25 09:00AM	RxSight, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RXST (PR Newswire) +10.53%
Aug-07-25 06:15PM	RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.70%
04:05PM	RxSight, Inc. Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 08:05AM	RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors (GlobeNewswire)
Aug-01-25 09:00AM	RxSight, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - RXST (PR Newswire)
Jul-31-25 04:15PM	Investors in RxSight, Inc. (RXST): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile)
04:02PM	Loading…
Jul-30-25 04:02PM	Investors in RxSight, Inc. (RXST): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile)
Jul-25-25 04:54PM	RxSight, Inc. (RXST) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 22, 2025 (Newsfile)
Jul-24-25 04:05PM	RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-09-25 03:00AM	RxSight Inc (RXST) Q2 2025 Earnings Call Highlights: Strategic Shifts Amid Market Challenges (GuruFocus.com) -37.84%
Jul-08-25 04:05PM	RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance (GlobeNewswire)
Jul-04-25 11:40AM	FMS vs. RXST: Which Stock Is the Better Value Option? (Zacks)
Jun-18-25 11:40AM	KMDA vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
11:40AM	FMS or RXST: Which Is the Better Value Stock Right Now? (Zacks)
May-31-25 05:59AM	Down Over 30%: Wells Fargo Says Now Is the Time to Load Up on These 2 Beaten-Down Stocks (TipRanks)
May-23-25 08:32AM	Do Options Traders Know Something About RxSight Stock We Don't? (Zacks)
May-20-25 04:10PM	RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum (GlobeNewswire)
10:55AM	Wells Fargo Upgrades RxSight (RXST), Sees LAL Technology as Undervalued (Insider Monkey)
May-08-25 03:31AM	RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Advances Amid ... (GuruFocus.com) -11.21%
May-07-25 11:04PM	RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript (Seeking Alpha) +6.81%
07:55PM	RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	RxSight, Inc. Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-30-25 04:05PM	RxSight, Inc. to Present at the Bank of America Healthcare Conference (GlobeNewswire)
10:01AM	RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-23-25 04:05PM	RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-04-25 11:46AM	JP Morgan downgrades RxSight on market, competitive pressures (Investing.com)
09:40AM	Block upgraded, Nvidia downgraded: Wall Streets top analyst calls (TipRanks)
03:00AM	RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ... (GuruFocus.com)
Apr-03-25 10:39PM	Preliminary Q1 2025 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents) -37.94%
05:57PM	?RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) (Seeking Alpha)
03:54PM	RxSight, Inc. (RXST) Q1 2025 Preliminary Results Conference Call (Transcript) (Seeking Alpha)
12:59PM	RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock (GuruFocus.com)
07:32AM	RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges (Benzinga)
Apr-02-25 08:00PM	RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance (GlobeNewswire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-25-25 04:05PM	RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Feb-26-25 02:15AM	RxSight Inc (RXST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Feb-25-25 05:55PM	RxSight, Inc. (RXST) Misses Q4 Earnings Estimates (Zacks)
04:05PM	RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance (GlobeNewswire)
01:36AM	What To Expect From RxSight Inc (RXST) Q4 2024 Earnings (GuruFocus.com)
Feb-11-25 04:10PM	RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025 (GlobeNewswire)
Jan-18-25 07:55AM	RxSight price target lowered to $43 from $66 at Needham (TipRanks)
Jan-12-25 09:30AM	RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance (GlobeNewswire)
Jan-02-25 04:05PM	RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-24 09:43AM	Do You Believe in the Long-Term Growth Potential of RxSight (RXST)? (Insider Monkey) -11.86%
Nov-20-24 12:00PM	RxSight (RXST) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-08-24 12:02PM	RxSight Inc (RXST) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Market ... (GuruFocus.com) -5.59%
Nov-07-24 07:00PM	RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3 (Zacks) -7.09%
04:05PM	RxSight, Inc. Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 07:16AM	What To Expect From RxSight Inc (RXST) Q3 2024 Earnings (GuruFocus.com) +5.80%
Oct-24-24 04:05PM	RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024 (GlobeNewswire)
Oct-15-24 06:10PM	RxSight, Inc. (RXST): A Visionary Small-Cap Stock Pick by Hedge Funds (Insider Monkey)
Oct-13-24 05:33PM	RxSight, Inc. (RXST): Top Investors Are Investing In This Small-Cap Stock Now (Insider Monkey)
Aug-22-24 04:05PM	RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences (GlobeNewswire)
Aug-19-24 03:43PM	RxSight Stock Sees Relative Strength Rating Rise To 91 (Investor's Business Daily)
Aug-12-24 09:55AM	Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect? (Zacks)
Aug-06-24 09:55AM	Q2 2024 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents) +17.34%
Aug-05-24 06:10PM	RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2 (Zacks)
04:05PM	RxSight, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
11:20AM	The 3 Best Med Tech Stocks to Buy Now (InvestorPlace)
Jul-29-24 09:35AM	Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround (Zacks)
Jul-22-24 04:05PM	RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024 (GlobeNewswire)
Jul-12-24 09:35AM	RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jul-10-24 10:59AM	Dow Flat As Nasdaq, S&P 500 Rise Again; Gold Stocks Rally, But These Growth Players Get Hit (Live Coverage) (Investor's Business Daily) -10.32%
Jun-18-24 01:50AM	Insider Sale: Director Julie Andrews Sells 15,625 Shares of RxSight Inc (RXST) (GuruFocus.com)
Jun-13-24 11:22AM	Eye Care Innovator In Buy Zone; 176% Growth Expected For IBD 50 Stock (Investor's Business Daily)
Jun-07-24 02:40PM	These 5 Companies Lost Money. Here's Why They're Still On The IBD 50. (Investor's Business Daily)
Jun-05-24 04:05PM	RxSight, Inc. To Participate in the Truist Securities Medtech Conference (GlobeNewswire)
May-30-24 04:00AM	Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board (GlobeNewswire)
May-28-24 12:00PM	What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now? (Zacks)
May-24-24 11:40AM	Why Top-Rated Medtech RxSight Has 20/20 Vision And Is Seeing 50% Growth (Investor's Business Daily)
May-13-24 04:58PM	RxSight Raises $115 Million From Public Offering of Shares (MT Newswires)
04:05PM	RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-08-24 09:15PM	RxSight, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:05PM	RxSight, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goldshleger Ilya	See remarks	Sep 25 '25	Option Exercise	4.27	23,445	99,998	65,691	Sep 26 04:07 PM
Weinberg Eric	See remarks	Jun 02 '25	Option Exercise	3.93	188,002	738,848	195,351	Jun 03 06:18 PM
Thunen Shelley B	See remarks	Apr 14 '25	Option Exercise	4.34	7,792	33,806	38,354	Apr 15 08:57 PM
Fountain Tamara	Director	Mar 12 '25	Sale	25.71	7,000	180,002	24,793	Mar 13 04:46 PM
TAMARA R FOUNTAIN	Director	Mar 12 '25	Proposed Sale	25.71	7,000	180,002		Mar 12 04:02 PM

CBLL

Ceribell Inc

RXST

RxSight Inc

Upgrade your FINVIZ experience